Pancreatic adenocarcinoma upregulated factor (PAUF) was recently reported to be a metastasis factor for pancreatic cancer cells. Here, we demonstrate a novel role for PAUF as a potent endothelial activator, promoting both angiogenesis and vascular permeability. Overexpression of PAUF in a mouse pancreatic cancer model resulted in increased tumor vascularity. Recombinant PAUF (rPAUF) enhanced proliferation, migration and capillary-like tube formation of human endothelial cells (ECs), consistently with increased neovascularization in vivo. rPAUF also increased endothelial permeability through the disruption of vascular endothelialcadherin-facilitated cell-cell junctions in vitro and induced vascular leakage in mouse skin. These effects were attenuated upon treatment with an antibody against PAUF. Moreover, PAUF evoked a time-and dose-dependent activation of extracellular signalregulated kinase (ERK)1/2, AKT and endothelial NO synthase (eNOS) in ECs, which are closely linked to rPAUF-induced angiogenesis. Finally, rPAUF upregulated the expression of C-X-C chemokine receptor 4 (CXCR4) in ECs and potentiated the in vitro and in vivo EC angiogenic responses to stromal cell-derived factor-1 (SDF-1), a ligand for CXCR4. Taken together, these data demonstrate that PAUF has a novel function in promoting angiogenesis and vascular permeability. Our findings suggest new possibilities for PAUF's role in the pathogenesis of angiogenesis-dependent diseases.
INTRODUCTION
Angiogenesis is the physiological process involving the growth of the new blood vessels from existing vessels. It has an important role in physiological and pathological conditions, including organ development during embryogenesis, chronic inflammation and malignant tumor development.
1,2 A large number of molecules, which are composed of growth factors, cytokines and lipid metabolites, are shown to be involved in pathophysiologic neovascularization by stimulating endothelial cells (ECs) directly or indirectly. Among these, vascular endothelial growth factor (VEGF), expressed by most cancer cell types and certain tumor stromal cells, is a potent proangiogenic factor that functions in tumor vascular development. 3 In addition, it facilitates tumor metastasis by providing an increased density of immature, highly permeable blood vessels with less basement membrane and fewer intercellular junction complexes than normal mature vessels. 4 Recently, we identified a novel gene named pancreatic adenocarcinoma upregulated factor (PAUF, also known as a paralog of ZG16p), 5 which is a 17 kDa secreted protein highly expressed in human pancreatic ductal adenocarcinoma (PDAC), but not in normal pancreatic ducts, acinar cells, interstitial cells and blood vessels. 6 PAUF has a crucial role in PDAC progression and metastasis. 7 The mechanism by which PAUF contributes to PDAC progression is not clearly established. However, it is likely that ligand binding has an essential role in PAUF signaling. We recently demonstrated that PAUF promotes pancreatic cancer progression and metastasis through the activation of intracellular signaling molecules such as extracellular signal-regulated kinase (ERK), c-Jun N-terminal kinase, and AKT. 7 Activation of these signaling molecules contributes to cell growth, motility and tumor cells invasion, providing insight into the mitogenic effect of PAUF. Moreover, activation of focal adhesion kinase is associated with PAUF-mediated survival and the increased adhesiveness of tumor cells. 8 PAUF also regulates gene expression through the activation of transcription factors such as cAMP response element-binding, E twenty-six-like transcription factor 1, c-Jun and activating transcription factor 2. 7 Although we did not elucidate the exact mechanism by which PAUF regulates the gene transcription of C-X-C chemokine receptor 4 (CXCR4), PAUF-upregulated CXCR4 is closely involved in pancreatic cancer cell motility and invasiveness. 7 In addition, it has been shown that PAUF interacts with the CXCR4-Toll-like receptor 2 (TLR2) complex in immune cells and inhibits TLR2-mediated nuclear factor kappa B activation, thus facilitating tumor growth and evading innate immune surveillance. 9 Although these studies describe potent effects mediated by PAUF, the specific receptor(s) responsible for PAUFinduced cellular activities is currently unknown.
Overall, previous studies suggest that PAUF secreted from tumor cells has an important role in modulating tumor progression and metastasis in the tumor microenvironment by promoting malignant transformation of cells and stimulating the production of pro-tumorigenic cytokines from non-tumor cells. However, there are limited data available regarding the vascular function of PAUF in ECs. In this study, we investigated the vascular function of PAUF and report that it potently promotes angiogenesis in vivo and directly enhances proliferation, migration and morphogenesis of ECs in vitro. Our data also demonstrate that PAUF has a significant effect on vascular permeability. We further provide evidence suggesting PAUF potentiates EC angiogenic responses to SDF-1 through upregulation of CXCR4 expression.
RESULTS

Enhanced tumor vascularity in PAUF-overexpressing tumors
We have previously shown that PAUF promotes tumorigenesis and metastasis in pancreatic cancer cell lines and mouse models. 7 Based on these results, we hypothesized that PAUF may have a novel biological function as an inducer of tumor angiogenesis, a process essential to tumor growth and metastasis. To determine whether PAUF induces angiogenesis, we first examined the density of microvessels in previously reported pancreatic tumors of mouse models established with stable cell lines, which express low (CFPAC-1) or high (Panc-1) levels of PAUF. 6, 7 As shown in Figure 1a , vascular density in the peripheral areas of PAUFoverexpressing tumors was significantly higher than that of the mock control tumors. In contrast, the vascular density in PAUF knockdown tumors was significantly reduced as compared with those from small hairpin RNA control tumors (Figure 1b) . However, Po0.05, **Po0.001 versus mock control or sh control. The proliferation assay (c, f ), migration assay (d, g), and capillary-like tube formation assay (e, h) were performed using CM from pancreatic cancer cell lines with PAUF overexpressed (Panc-1) or knocked down (CFPAC-1). Three independent experiments were performed with duplicate samples in each. Data are reported as mean±s.e. *Po0.01, **Po0.001 versus mock control or sh control.
there was no significant difference in the vascular density between the two groups in central tumor areas (data not shown). To further examine the effects of PAUF on tumor angiogenesis, we analyzed its angiogenic activities in vitro using conditioned media (CM) from pancreatic cancer cell lines with PAUF overexpressed or knocked down. We observed a significant increase in proliferation, migration and capillary-like tube formation in human umbilical vein ECs (HUVECs) incubated with CM derived from PAUFoverexpressing cells (Panc-1_PAUF). Conversely, incubation with CM from cells with PAUF knocked down (CFPAC-1_sh PAUF) led to a reduction in these cellular activities (Figures 1c-h ). These cellular responses were consistently observed in other stable pancreatic cancer cell lines, MiaPaCa-2 and BxPC-3. (Supplementary Figure 1) . Together, our results suggest that PAUF may have potent angiogenic activity that leads to blood vessel formation in tumors.
PAUF induces angiogenesis in vitro and in vivo To determine whether PAUF has a direct effect on angiogenesis in vivo, we employed the Matrigel implant assay in mice. As shown in Figure 2a , PAUF-containing Matrigel plugs were red in color in a dose-dependent manner, implying neovascularization. As a positive control, VEGF Matrigel plugs were found to have a similar color to that of PAUF-treated plugs (data not shown). Quantification of CD31 immunostaining of the Matrigel plugs indicated that PAUF markedly increases angiogenesis as compared with control (Figures 2b and c) . To further assess the roles of recombinant PAUF (rPAUF) on angiogenesis, we evaluated the effect of PAUF on endothelial-cell sprouting in aortic ring segments. rPAUF significantly induced endothelial-cell sprouting in a dosedependent manner (Figures 2d and e) .
The process of angiogenesis is complex and involves several discrete steps, including extracellular matrix degradation, proliferation, migration and morphological differentiation of ECs to form tubes. Thus, we assessed the ability of PAUF as an angiogenic stimulus using in vitro angiogenesis models. We first examined the effect of PAUF on HUVEC proliferation and found that addition of rPAUF increased the total number of cells after 48 h in a dosedependent manner (Figure 3a) . We next determined the effect of rPAUF on EC chemotactic motility and morphological differentiation. As shown in Figures 3b and c and Supplementary Figure 2 , PAUF significantly enhanced the chemotactic motility and capillary-like tube formation of HUVECs in a dose-dependent manner. Near-maximal activity of rPAUF was observed at 0.5 mg/ml, with a comparable effect compared with the optimal concentration of VEGF (0.02 mg/ml). To further confirm the angiogenic effects of rPAUF in HUVECs, we used a PAUF antibody to block its functional activity. 6 The PAUF-neutralizing antibody significantly reduced rPAUF-induced angiogenic activities (Figures 3d-f ). Taken together, these results suggest that PAUF has potent angiogenic activity in vivo and in vitro.
The angiogenic effect of PAUF is not related to VEGF activity or expression of proangiogenic factors Although our results demonstrate that PAUF has potent angiogenic activity, it was unclear whether PAUF acted directly on ECs or indirectly regulated angiogenesis through the induction of other factors. A number of angiogenic inducers, including tumor necrosis factor-a (TNF-a), transforming growth factor-b (TGF-b) and interleukin-1b (IL-1b) act directly on ECs and/or indirectly via induction of VEGF expression. Thus, we tested the possibility that the effect of PAUF on angiogenesis is mediated through expression of VEGF. As shown in Figure 4a , rPAUF had no effect on the levels of VEGF protein as measured by ELISA. In addition, a VEGF-neutralizing antibody had no effect on rPAUFinduced angiogenic activities (Figures 4b-d) but significantly reduced VEGF-induced angiogenesis (data not shown). Furthermore, there was no significant alteration in the expression of other genes involved in angiogenesis including platelet-derived growth factor-BB (PDGF-BB), fibroblast growth factor-2 (FGF-2), SDF-1, angiopoietin-1 (Ang-1), hepatocyte growth factor (HGF) and insulin growth factor-1 (Supplementary Figure 3) . These results indicate that PAUF-induced angiogenesis is not due to the induction of VEGF expression, suggesting that PAUF may act as a direct angiogenic activator in ECs.
PAUF induces activation of intracellular signaling molecules in HUVECs
We previously reported that PAUF is a secretory protein that stimulates intracellular signaling molecules to induce functional changes in pancreatic cancer cells and immune cells.
7,9 Therefore, we investigated whether PAUF can also activate intracellular signals involved in proliferation, migration, or morphogenesis of ECs. HUVECs were exposed to various concentrations of rPAUF, and the activation of ERK1/2, AKT and endothelial NO synthase (eNOS) were analyzed by western blot analysis using phosphoantibodies for each protein. rPAUF induced the activation of these signaling molecules in a dose-and time-dependent manner (Figures 5a, b) . To further determine whether the activation of these signaling molecules is associated with the angiogenic activities of PAUF, we tested the effect of PAUF in the presence of specific inhibitors of these signaling pathways. Treatment of PD98059 (an ERK inhibitor), wortmannin (a PI3K inhibitor), or L-NAME (L-nitro-arginine methyl ester, a nitric oxide synthase inhibitor) significantly attenuated the PAUF-enhanced proliferation, chemotactic motility and capillary-like tube formation of HUVECs (Figures 5c-e; Supplementary Figure 4) . These data suggest that the angiogenic function of PAUF is mediated by the activation of the ERK and PI3K/AKT/eNOS signaling pathways.
PAUF induces EC permeability in vitro and in vivo Vasculature in solid tumors are known to show a higher vascular permeability than normal vessles, similar the inflammatory tissues. 10 Hyperpermeable tumor vessels provide a basic way for tumor cells to move from the primary site to the blood circulation and facilitate tumor metastasis to distant organ. 11 Therefore, to determine whether PAUF induces vascular hyperpermeability in vivo, a modified Miles assay for vascular permeability was performed using rPAUF. rPAUF strongly induced vascular hyperpermeability in mouse skin, as indicated by increased leakage of Evans blue dye (Figure 6a ). Spectrophotometric measurements of the extravasated Evans blue dye revealed that the increase was dose-dependent in relation to rPAUF (Figure 6b ). In addition, treatment with rPAUF increased fluorescein isothiocyanate (FITC)-dextran diffusion through the pores of transwell membranes in a HUVEC monolayer culture in a dose-dependent manner (Figure 6c ).
Vascular endothelial permeability is maintained by the endothelial junction proteins VE-cadherin and occludin. 12 We tested the effect of PAUF on adherens junction formation by immunostaining with a VE-cadherin antibody. In confluent ECs, VE-cadherin is localized at cell-cell contacts. When HUVECs were treated with rPAUF, the level of VE-cadherin at cell-cell junctions significantly decreased. Treatment with a PAUF-neutralizing antibody blocked this effect (Figure 6d ).
Tyrosine phosphorylation of VE-cadherin in ECs is an important mechanism associated with loss of stability of cell-cell adhesion, which is involved in modulating endothelial permeability. 13 It has been reported that Src kinase-dependent tyrosine phosphorylation of VE-cadherin induces the disruption of cell-cell contacts in Ecs.
14 Treatment of confluent HUVECs with rPAUF increased the phosphorylation of VE-cadherin and Src (Figure 6e ) and the PAUFneutralizing antibody inhibited this phosphorylation (Figure 6f) . Importantly, blocking Src with the specific inhibitor PP2 significantly reduced rPAUF-induced VE-cadherin phosphorylation and vascular permeability (Supplementary Figure 5) . Taken together, these results suggest that PAUF increases vascular permeability through the induction of Src-dependent VE-cadherin phosphorylation.
PAUF potentiates angiogenic responses of ECs to SDF-1 through upregulation of CXCR4 expression Our previous studies demonstrated that PAUF upregulates CXCR4 expression in pancreatic cancer cells, thus enhancing pancreatic cancer progression. 7 As SDF-1 is highly expressed in patients with PDAC and its expression is associated with worse prognosis, 15, 16 we raised the possibility that PAUF might increase CXCR4 expression in ECs, resulting in potentiating angiogenic responses of ECs to SDF-1. First, we evaluated whether PAUF induces expression of CXCR4 in ECs and found it increased CXCR4 mRNA and protein in a time-dependent manner (Figure 7a) . Moreover, co-treatment with rPAUF and SDF-1 potentiated the proliferation, chemotactic motility and capillary-like tube formation of HUVECs. Consistent with this finding, AMD3100, a specific CXCR4 antagonist, significantly attenuated the rPAUF-potentiated angiogenic responses to SDF-1 (Figures 7b-d) . We then performed Matrigel implant assays to examine the effect of PAUF on SDF-1-induced neovascularization in vivo. As shown in Figures 7e and f and Supplementary Figure 6 , rPAUF-and SDF-1-containing Matrigel plugs exhibited significantly higher densities of CD31-positive ECs compared with those with SDF-1 alone. This angiogenic response was significantly reduced by simultaneous treatment with AMD3100. These results suggest that PAUF acts as a direct inducer of angiogenesis but also indirectly potentiates the angiogenic activities of SDF-1 via upregulation of CXCR4 in ECs.
DISCUSSION
The present study has shown for the first time that PAUF, a novel activator of ECs, promotes angiogenesis and vascular permeability in vitro and in vivo. Moreover, PAUF upregulates expression of CXCR4 in ECs and potentiates angiogenic responses to SDF-1. These findings suggest that PAUF may be involved in angiogenesis-dependent vascular diseases including tumors.
Angiogenesis is an indispensable process for the growth and metastasis of most solid malignancies. It is initiated by bioactive molecules including growth factors, cytokines and metabolites that are secreted from tumor and stromal cells. Targeting angiogenesis to reduce tumor progression and metastasis might yield promising strategies for combination therapy. Although pancreatic cancer is not a grossly vascular tumor, this malignancy often exhibits enhanced foci of EC proliferation. 17, 18 Moreover, several studies have reported a positive correlation between blood vessel density and disease progression in pancreatic cancer, indicating the important role of angiogenesis in this disease. [19] [20] [21] In fact, numerous factors including epidermal growth factor, TGF-a, HGF, FGFs, VEGF and PDGF-b are known to be involved in pancreatic cancer angiogenesis. 18, 22 Among these, VEGF is Three independent experiments were performed with duplicate samples in each. Data are reported as mean ± s.e. *Po0.01, **Po0.001.
believed to be critical for pancreatic cancer angiogenesis.
20,23-25
Previous studies have shown that VEGF expression correlates with microvessel density and disease progression. Despite its prominent expression and clinicopathologic relevance, a recent study demonstrated that the addition of bevacizumab, an anti-VEGF monoclonal antibody, to chemotherapy did not provide any significant benefit. 26 This finding suggests that other factors are likely to be involved in pancreatic cancer angiogenesis and the identification of novel targets for anti-angiogenesis therapy is imperative.
Recently, we identified a novel secretory protein, PAUF, which is highly expressed in human PDAC. 7 Immunohistochemical analysis showed that alterations in PAUF expression levels are correlated with microvessel density in mouse models (Figure 1 ). Tumors overexpressing PAUF displayed significantly enhanced vascular density as compared with mock control tumors. Consistently, tumors with PAUF knocked down had less tumor vasculature when compared with tumors transfected with control small hairpin RNA. rPAUF also promoted vessel sprouting from explanted mouse aortic rings and neovascularization in Matrigel plugs inserted in mice skin (Figure 2 ). We also report that rPAUF increased EC proliferation, migration and tubular network formation, similar to effects observed with VEGF in vitro. Treatment with a PAUF-neutralizing antibody abrogated the observed angiogenic effects (Figure 3 ). Several cytokines that induce angiogenesis, such as IL-1b, exert their action through upregulation of VEGF. 27, 28 However, the effect of rPAUF on the vasculature likely is not mediated by VEGF, because rPAUF does not increase the expression of VEGF in ECs. In addition, blocking VEGF signaling with a neutralizing antibody did not significantly reduce the angiogenic action of rPAUF, suggesting that the angiogenic effect of rPAUF is not the secondary effect of VEGF induction.
Our data also demonstrate the prominent role of PAUF in the regulation of vascular permeability. Vascular permeability is a feature observed in areas of diseased tissue associated with solid tumors, diabetic retinopathy and chronic inflammation. 29, 30 In particular, tumor vessels are leaky structures with increased endothelial permeability correlating with interstitial hypertension, poor delivery of therapeutic agents and the malignant potential of tumors. 31 VEGF, the best characterized angiogenic stimulus, was originally identified as a vascular permeability factor and its vasopermeability activity is involved in numerous vascular pathophysiologies. 31 Whereas VEGF promotes both angiogenesis and vascular permeability, other angiogenic factors such as basic fibroblast growth factor and platelet-derived growth factor have no significant effect on permeability. 29 In the case of Ang-1, it inhibits endothelial permeability despite its prominent angiogenic activities. 32 The data presented here show that PAUF, like VEGF, promotes both angiogenesis and vascular permeabilization. Treatment with rPAUF increased vessel leakage in mice as well as EC junctional permeability (Figures 6a-d) . Vascular permeability is regulated by endothelial junction proteins including VE-cadherin and occludin. Src-dependent tyrosine phosphorylation of VE-cadherin is involved in loosening the cell-cell contacts of established vessels upon VEGF stimulation. 13, [33] [34] [35] Similarly, our results showed that rPAUF induces phosphorylation of VE-cadherin and Src. Blocking Src signaling with a specific inhibitor prevented rPAUF-induced VE-cadherin Figure 5 . PAUF activates intracellular signaling molecules in HUVECs in a time and dose-dependent manner. HUVECs were stimulated with 0.5 mg/ml PAUF for the indicated times (a) or with various concentrations of rPAUF for 20 min (b). Whole cell lysates were prepared and used for western blot analysis with the respective P-ERK, ERK, P-AKT, AKT, P-eNOS and eNOS antibodies. (c-e) HUVECs were preincubated for 30 min in the presence or absence of PD98059 (20 mM), Wortmannin (100 nM) or L-NAME (1 mM) prior to stimulation with rPAUF (0.5 mg/ml). Proliferation (c), migration (d) and capillary-like tube formation (e) were performed as described above. Three independent experiments were performed with duplicate samples in each. Data are reported as mean ± s.e. Figure 5) . These results imply that the endothelial functions of PAUF are quite similar to those of VEGF. These properties of PAUF in the vasculature may provide valuable clues for predicting the pathologic role of PAUF in angiogenesisdependent vascular diseases, and suggest that it may be considered as a therapeutic target.
We next asked how PAUF induces angiogenesis in ECs. We recently reported that PAUF enhances pancreatic cancer cell motility and invasion through activating ERK, c-Jun N-terminal kinase and AKT in an autocrine manner. 7 Consistent with these previous results, rPAUF also induced activation of ERK, AKT and eNOS in ECs. Blockade of these molecules with specific inhibitors prevented PAUF-induced angiogenesis (Figures 5c-e) . Thus, it is clear that these signaling pathways are required for the angiogenic activities of PAUF. We have previously demonstrated that PAUF is an endogenous mammalian ligand of TLR2 and TLR4 and activates TLR-mediated ERK, c-Jun N-terminal kinase and p38 signaling cascades in immune cells, consequently producing selective cytokines for tumor progression and metastasis.
9 TLR2 and TLR4 are expressed in the endothelium, implicated in angiogenesis and recognize a broad range of proteins. 36, 37 PAUF-activated signaling pathways were found to be critical downstream molecules of TLRs. 38 Thus, we hypothesized the involvement of TLRs in PAUF-induced angiogenesis in ECs. However, we did not find the functional association of PAUF with TLR2 or TLR4 on ECs in vitro (Supplementary Figure 7) , suggesting that PAUF may exert its angiogenic actions independent of TLR2 and TLR4. Furthermore, PAUF did not induce the phosphorylation of receptor tyrosine kinases, which have a pivotal role in angiogeneis (Supplementary Figure 8) . These data presented in this study indicate that the effects of PAUF promoting angiogenesis may be mediated by different kinds of receptors involved in angiognesis. HUVECs were grown to confluence on gelatin-coated plates and treated with rPAUF (0.5 mg/ ml) alone or rPAUF (0.5 mg/ml) plus the neutralizing PAUF antibody (30 mg/ml) for 2 h. Arrows indicate disruption of VE-cadherin. (e) Confluent HUVECs were stimulated with rPAUF (0.5 mg/ml) for the indicated times. The cell lysates were immunoprecipitated using a phosphotyrosine antibody followed by western blot analysis with VE-cadherin antibody or analyzed by western blot analysis with P-Src and Src antibodies. (f ) HUVECs were treated with PBS, control antibody (30 mg/ml), rPAUF (0.5 mg/ml) alone, rPAUF (0.5 mg/ml) plus control antibody (30 mg/ml), or rPAUF (0.5 mg/ml) plus PAUF antibody (30 mg/ml) for 30 min. Immunoprecipitation and western blot analysis were performed.
This study provides further insight into the mechanism by which PAUF potentiates EC angiogenic responses to SDF-1. Our previous report demonstrated that PAUF upregulates CXCR4 expression in pancreatic cancer cells and enhances tumor cell migration. 7 The CXCR4/SDF-1 receptor-ligand system promotes tube-like formation and migration of ECs 39 and induces neovascularization in pathological conditions. 15, 40 It has also been shown that the CXCR4/SDF-1 system induces tumor angiogenesis by synergizing with VEGF secreted from tumors. 41 rPAUF also increased to stimulation with rPAUF (0.5 mg/ml), SDF-1 (0.1 mg/ml) or rPAUF (0.5 mg/ml) plus SDF-1 (0.1 mg/ml). Proliferation (b), migration (c) and capillarylike tube formation (d) were performed as described above. Three independent experiments were performed with duplicate samples in each. Data are reported as mean±s.e. # Po0.05, *Po0.01, **Po0.001. (e, f ) C57/BL6 mice (six animals per treatment group) were injected with 0.6 ml of Matrigel containing phosphate-buffered saline (PBS) (control), AMD3100 (20 mM), PAUF (5 mg/ml), SDF-1 (0.1 mg/ml), rPAUF (5 mg/ml) plus SDF-1 (0.1 mg/ml) or rPAUF (5 mg/ml) plus SDF-1 (0.1 mg/ml) plus AMD3100 (20 mM). (e) The plugs were stained for infiltrating ECs using the CD31 antibody. expression of CXCR4 and co-treatment with rPAUF and SDF-1 potentiated the proliferation, chemotactic motility and capillarylike tube formation of ECs. The inhibitor AMD3100 reduced rPAUFmediated angiogenic responses of SDF-1 in vitro and in vivo ( Figure 7 and Supplementary Figure 6) . However, no direct interaction was observed between rPAUF and CXCR4 in ECs (Supplementary Figure 9a) . In addition, pretreatment of AMD3100 did not inhibit rPAUF-induced ERK phosphorylation, indicating that it is unlikely that PAUF binds to or activates CXCR4 directly (Supplementary Figure 9b) .
Our observations propose a dual model for the regulation of angiogenesis by PAUF. First, PAUF secreted from pancreatic cancer cells can directly promote angiogenesis by enhancing vessel formation and neovascularization. However, PAUF can also regulate angiogenesis indirectly by rendering ECs more responsive to SDF-1 via upregulation of CXCR4 expression.
In summary, the present study provides the first evidence that PAUF promotes angiogenesis and endothelial permeability and potentiates angiogenic responses of ECs to SDF-1 through upregulation of CXCR4 expression. These findings demonstrate that increased PAUF levels in the tumor microenvironment may lead directly to endothelial activation and thus make an important contribution to tumor angiogenesis. Finally, our results suggest that PAUF may be a promising therapeutic target in angiogenesisdependent vascular diseases. Studies are currently underway to elucidate the specific receptor(s) involved and the underlying molecular mechanism for PAUF-dependent gene regulation.
MATERIALS AND METHODS
Cell culture, reagents and tumors
HUVECs were isolated by collagenase treatment as previously described 42 and used between passages 2 and 7. Cells were grown in M199 media (Invitrogen, Carlsbad, CA, USA) supplemented with 20% fetal bovine serum (FBS) (JRS Inc., Woodland, CA, USA), 100 U/ml penicillin/streptomycin, 5 ng/ml basic fibroblast growth factor (bFGF) (Millipore, Billerica, MA, USA) and 5 units/ml heparin (Sigma-Aldrich, St Louis, MO, USA). rPAUF and an anti-PAUF polyclonal antibody were prepared as previously described. 6 The MEK inhibitor PD98059 was purchased from Cell Signaling Technology (Danvers, MA, USA). Wortmannin and L-nitro-arginine methyl ester (L-NAME) were purchased from Sigma-Aldrich. Recombinant human SDF-1a (CXCL12) was purchased from PeproTech (Rocky Hill, NJ, USA). Recombinant human VEGF protein was from R&D system (Minneapolis, MN, USA). All antibodies used in this study are shown in Supplementary Table S1. All tumors analyzed in this study were derived from mouse models of previous report. 7 Briefly, Tumors of subcutaneous xenograft model were grown to approximately 300-400 mm 3 in size and density of microvessels was determined by immunohistochemical analysis of CD31 in peripheral or central tumor areas.
In vitro cell permeability assay Cell permeability was analyzed by measuring the diffusion of fluorescein isothiocyanate (FITC) -conjugated dextran (Sigma-Aldrich) through the cell monolayer. HUVECs were plated onto gelatin-coated transwell inserts with 12 mm polycarbonate filters of 0.4 mm pore size (Corning, Costar, NY, USA) and cultured to confluence in growth media. The cells were then incubated in M199 containing 1% FBS for 6 h, and various concentrations of rPAUF were added. After 1 h in the presence of rPAUF, FITC-dextran was loaded in the upper compartment of transwell. The amount of FITC-dextran that passed through the endothelial monolayer to the lower chamber was measured after 30 min by a fluorescent reader (Victor2; Perkin Elmer/Wallac, Waltham, MA, USA).
Ex vivo mouse aortic ring assay
Mouse aortic rings were obtained by cutting 1 mm pieces from the thoracic aorta of 7-week-old C57/BL6 male mice (Koatech Co., Pyeongtaek, Korea). Rings were placed into 48-well plates precoated with Matrigel and sealed in place with an overlay of 40 ml of Matrigel. rPAUF was added to the wells and serum-free endothelial basal media (Lonza, Basel, Swizerland) was added to a final volume of 200 ml. The plates were incubated and microvessel sprouting from the aortic ring was photographed on day 10. This assay tested five rings per group. The sprouting vessels were quantified using the ImageJ software program (National Institutes of Health, Bethesda, MD, USA).
In vivo Matrigel plug assay C57/BL6 male mice (Koatech Co.) were injected subcutaneously in the right flank with 600 ml of Matrigel containing rPAUF. After 7 days, the mice were killed. The solid Matrigel plugs were carefully removed without the surrounding connective tissue and then photographed. The plugs were embedded in OCT compound (Sakura, Torrance, CA, USA) for examination of EC infiltration. The number of ECs within each plug was assessed by immunostaining with CD31 antibody (1:50 dilution). All animal studies were in compliance with the policies of the animal care and use committee of the Korean Research Institute of Bioscience and Biotechnology.
Miles assay for vascular permeability C57/BL6 mice were injected intravenously with Evans blue dye (100 ml of a 1% solution in 0.9% NaCl). After 10 min, 10 ml of rPAUF (1 mg/ml or 5 mg/ml) or PBS was injected intradermally into the pre-shaved back skin. After 30 min, the mice were killed, and an area of skin surrounding the intradermal injection sites was removed. The Evans blue dye was extracted from the skin by incubation with formamide for 4 days at room temperature. The absorbance of the extracted dye was measured at 620 nm with a spectrophotometer.
Immunohistochemical and immunocytochemical staining
For immunohistochemical staining, paraffin-embedded tumor specimens were blocked with 3% bovine serum albumin in phosphate-buffered saline and incubated with the CD31 antibody (1:50 dilution) overnight at 4 1C, followed by Cy5-conjugated goat anti-rat antibody (1:100 dilution) for 1 h at room temperature in dark. After washing in phosphate-buffered saline, specimens were stained for 5 min with DAPI (4 0 ,6 diamidino-2-phenylindole; Sigma-Aldrich). Fluorescent images were acquired using confocal microscopy (Carl Zeiss, LSM510 META: X400, Jena, Germany). For immunofluorescence staining, HUVECs were fixed with 3.7% formaldehyde for 10 min at room temperature and then permeabilized with 0.1% Triton X-100 in PBS for 30 min. The cells were then stained with an antibody to VE-cadherin (1:100 dilution) for 2 h at room temperature, followed by a FITC-conjugated secondary antibody (1:200 dilution) for 1 h. Visualization of cells was performed using confocal microscopy (Carl Zeiss).
Statistical analysis
Data are presented as mean ± s.d. or ± s.e., and statistical comparisons between groups were performed using one-way analysis of variance (ANOVA) followed by Student t test.
Standard methods for HUVEC proliferation, migration, capillary-like tube formation, ELISA, phospho-receptor tyrosine kinase array, western blot analysis and quantitative reverse transcription-PCR analysis are described in the Supplementary Materials and methods section.
